Tag: MannKind Corp

Finance

Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE) announced that PROFILE 1014, a phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. Pfizer Inc. (NYSE:PFE) stock performance was 1.13% in last session and finished the day at $32.18. … Continue reading Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis
Finance

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Colin Pettis
Finance

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Jayne Crisman
Finance

Worth watching Stocks: Arch Coal (NYSE:ACI), MannKind Corporation (NASDAQ:MNKD), AK Steel Holding (NYSE:AKS), Arena Pharmaceuticals (NASDAQ:ARNA)

Arch Coal Inc (NYSE:ACI) has been given a consensus rating of “Hold” by the eighteen brokerages that are presently covering the company, AnalystRatingsNetwork.com reports. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating on the company. Arch Coal Inc (NYSE:ACI) stock performance was -0.64% in last session and finished the … Continue reading Worth watching Stocks: Arch Coal (NYSE:ACI), MannKind Corporation (NASDAQ:MNKD), AK Steel Holding (NYSE:AKS), Arena Pharmaceuticals (NASDAQ:ARNA)

Kristen Barton
Finance

Biotech Active Stocks: Arrowhead Research (NASDAQ:ARWR), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX), MannKind Corporation (NASDAQ:MNKD)

Arrowhead Research Corp (NASDAQ:ARWR) stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank in a report issued on Monday, American Banking News.com reports. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was -16.09% in last session and finished the day at $17.37. Traded volume was 7.56million shares in the last session and the average volume of the stock remained 1.44million shares. The beta of … Continue reading Biotech Active Stocks: Arrowhead Research (NASDAQ:ARWR), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX), MannKind Corporation (NASDAQ:MNKD)

Chris Lewis
Finance

Biotech Active Stocks: Mast Therapeutics Inc (NYSEMKT:MSTX), Geron Corporation (NASDAQ:GERN), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Mast Therapeutics Inc (NYSEMKT:MSTX) announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires’ lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension. Mast Therapeutics Inc (NYSEMKT:MSTX) stock performance was 12.12% in last session and finished the day at $0.828. Traded volume was … Continue reading Biotech Active Stocks: Mast Therapeutics Inc (NYSEMKT:MSTX), Geron Corporation (NASDAQ:GERN), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Kevin Long